TDAC news

Translational Development Acquisition Corp. noted that ProLogium filed an initial Form F-4 with the SEC to support the de-SPAC merger announced on May 27. This regulatory filing increases transparency and signals continued positive momentum toward transaction finalization.

TDAC shareholders voted 95% in favor of extending the SPAC life, retaining $156.8 million in the trust following the redemption of 15% of shares. This overwhelming support demonstrates strong investor confidence in the SPAC's proposed merger with Prologium, the emerging battery technology leader.

Translational Development Acquisition Corp. extended its business combination deadline from June 24, 2026 to up to 12 additional months with sponsor funding. The amendment allows the SPAC to consummate a merger while providing public shareholders redemption rights if no deal closes by the extended d…

TDAC, a blank check company, has entered into a merger agreement with Prologium Holding Inc. dated May 27, 2026, involving two sequential mergers that will result in Prologium becoming a wholly-owned subsidiary. The transaction represents a significant business combination for the SPAC seeking to es…